Talphera (TLPH) Operating Income (2014 - 2026)
Talphera's (TLPH) quarterly Operating Income came in at -$3.9 million in Q1 2026, down 35.39% year-on-year from -$6.1 million in Q1 2025, and down 14.34% quarter-over-quarter from -$3.5 million in Q4 2025.
Talphera (TLPH) Operating Income (2014 - 2026) Analysis & Trends
Talphera's Operating Income history runs 13 years deep, the most recent figure standing at -$3.9 million for Q1 2026.
- On a quarterly basis, Operating Income fell 35.39% year-over-year to -$3.9 million in Q1 2026; TTM through Mar 2026 was -$14.5 million, a 4.2% decrease from a year earlier, with the FY2025 full-year figure at -$13.5 million, up 11.59% from the prior year.
- Operating Income retreated to -$3.9 million in Q1 2026 per TLPH's latest filing, from -$3.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$210000.0 in Q1 2023 and bottomed at -$10.0 million in Q2 2022.
- The 5-year median for Operating Income is -$3.9 million (2026), against an average of -$4.3 million.
- Across the five-year window, Operating Income soared 97.67% in 2023 and sank 1917.62% in 2024, its largest moves.
- Year by year, Operating Income stood at -$5.9 million in 2022, then advanced by 27.23% to -$4.3 million in 2023, then surged by 30.05% to -$3.0 million in 2024, then decreased by 15.25% to -$3.5 million in 2025, then retreated by 14.34% to -$3.9 million in 2026.
- Per Business Quant, the three latest TLPH Operating Income figures stand at -$3.9 million (Q1 2026), -$3.5 million (Q4 2025), and -$3.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 325.80 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Talphera | 47.31 Mn | 9.48 Mn | - | -3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.95 Mn |
| Dec 31, 2025 | -3.45 Mn |
| Sep 30, 2025 | -3.42 Mn |
| Jun 30, 2025 | -3.69 Mn |
| Mar 31, 2025 | -2.92 Mn |
| Dec 31, 2024 | -3.00 Mn |
| Sep 30, 2024 | -3.75 Mn |
| Jun 30, 2024 | -4.27 Mn |
| Mar 31, 2024 | -4.24 Mn |
| Dec 31, 2023 | -4.28 Mn |
| Sep 30, 2023 | -3.31 Mn |
| Jun 30, 2023 | -3.97 Mn |
| Mar 31, 2023 | -210,000.00 |
| Dec 31, 2022 | -5.89 Mn |
| Sep 30, 2022 | -4.52 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -9.00 Mn |
| Dec 31, 2021 | -8.18 Mn |
| Sep 30, 2021 | -8.63 Mn |
| Jun 30, 2021 | -10.02 Mn |